Cargando…

Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces “angiogenic switch off” in a hepatoma mouse model

“Angiogenic switch off” is one of the ideal therapeutic concepts in the treatment of cancer. However, the specific molecules which can induce “angiogenic switch off” in tumor have not been identified yet. In this study, we focused on von Hippel-Lindau protein (pVHL) in hepatocellular carcinoma (HCC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwamoto, Hideki, Nakamura, Toru, Koga, Hironori, Izaguirre-Carbonell, Jesus, Kamisuki, Shinji, Sugawara, Fumio, Abe, Mitsuhiko, Iwabata, Kazuki, Ikezono, Yu, Sakaue, Takahiko, Masuda, Atsutaka, Yano, Hirohisa, Ohta, Keisuke, Nakano, Masahito, Shimose, Shigeo, Shirono, Tomotake, Torimura, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782957/ https://www.ncbi.nlm.nih.gov/pubmed/27119112 http://dx.doi.org/10.1038/mto.2015.20

Ejemplares similares

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury
por: Abe, Mitsuhiko, et al.
Publicado: (2017)

High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine
por: Wada, Fumitaka, et al.
Publicado: (2018)

Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020)

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound
por: Kamachi, Naoki, et al.
Publicado: (2021)

Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma
por: Okamura, Shusuke, et al.
Publicado: (2022)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
por: Iwamoto, Hideki, et al.
Publicado: (2020)

Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
por: Suzuki, Hiroyuki, et al.
Publicado: (2023)

Von Hippel-Lindau Disease
por: Hes, Frederik J, et al.
Publicado: (2005)

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016)

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis
por: Shirono, Tomotake, et al.
Publicado: (2021)

Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion
por: Niizeki, Takashi, et al.
Publicado: (2021)

Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study
por: Shirono, Tomotake, et al.
Publicado: (2021)

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
por: Shimose, Shigeo, et al.
Publicado: (2023)

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
por: Torimura, Takuji, et al.
Publicado: (2016)

Von Hippel-Lindau Disease and the Eye
por: Karimi, Saeed, et al.
Publicado: (2020)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma
por: Shirono, Tomotake, et al.
Publicado: (2022)

Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata
por: Ohh, Michael, et al.
Publicado: (2022)

A Review of Von Hippel-Lindau Syndrome
por: Varshney, Neha, et al.
Publicado: (2017)

Cardiac Involvement in Von Hippel-Lindau Disease
por: Valero, Ernesto, et al.
Publicado: (2016)

Ocular Manifestations of von Hippel-Lindau Disease
por: Ruppert, Misty D, et al.
Publicado: (2019)

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
por: Zaizen, Yuki, et al.
Publicado: (2021)

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
por: Shimose, Shigeo, et al.
Publicado: (2020)

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Hemangioblastomatosis in a patient with von Hippel-Lindau disease
por: Hanse, M. C. J., et al.
Publicado: (2007)

The incidence of consecutive manifestations in Von Hippel-Lindau disease
por: van der Horst-Schrivers, Anouk N. A., et al.
Publicado: (2019)

Pathology of the Nervous System in Von Hippel-Lindau Disease
por: Vortmeyer, Alexander O., et al.
Publicado: (2015)

Resection of von Hippel Lindau Related Brainstem Hemangioblastoma
por: Maggio, Dominic, et al.
Publicado: (2019)

Clear cell chondrosarcoma in Von Hippel-Lindau disease
por: Dreijerink, Koen M. A., et al.
Publicado: (2019)

Von Hippel-Lindau Disease Presenting as Obstructive Jaundice
por: Giri, Suprabhat, et al.
Publicado: (2020)

Von Hippel-Lindau syndrome with pancreatic adenocarcinoma (with videos)
por: Zhang, Chenchen, et al.
Publicado: (2021)

Von Hippel-Lindau disease: A case report
por: Neupane, Durga, et al.
Publicado: (2022)

Vestibular Function in Children With Von Hippel–Lindau Disease
por: Fatih Turgut, Nesrettin, et al.
Publicado: (2021)

Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis
por: Nakamura, Toru, et al.
Publicado: (2016)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjvej6a4sagijrtdtdeje9fk1n